Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer.

[1]  E. Perez,et al.  Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Gnant.  Management of Bone Loss Induced by Aromatase Inhibitors , 2006, Cancer investigation.

[3]  M. Dimopoulos,et al.  Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Markiewicz,et al.  Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. , 2005, Journal of the American Dental Association.

[5]  R. Marx,et al.  Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. , 2005, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[6]  E. McCloskey,et al.  The causes and treatment of bone loss associated with carcinoma of the breast. , 2005, Cancer treatment reviews.

[7]  A. M. López,et al.  Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. , 2005, Archives of internal medicine.

[8]  J. Zerwekh,et al.  Severely suppressed bone turnover: a potential complication of alendronate therapy. , 2005, The Journal of clinical endocrinology and metabolism.

[9]  T. Powles,et al.  Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] , 2006, Breast Cancer Research.

[10]  J. Kanis,et al.  Clodronate Reduces Vertebral Fracture Risk in Women With Postmenopausal or Secondary Osteoporosis: Results of a Double‐Blind, Placebo‐Controlled 3‐Year Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  R. Marx.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[12]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  M. Stockler,et al.  Bisphosphonates for breast cancer. , 2005, The Cochrane database of systematic reviews.

[14]  T. Powles,et al.  Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Li,et al.  Bisphosphonate Treatment Suppresses Not Only Stochastic Remodeling but Also the Targeted Repair of Microdamage , 2001, Calcified Tissue International.

[16]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[17]  M. Seibel,et al.  Molecular Markers of Bone Turnover: Biochemical, Technical and Analytical Aspects , 2000, Osteoporosis International.

[18]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[19]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[20]  T. Spector,et al.  A high incidence of vertebral fracture in women with breast cancer , 1999, British Journal of Cancer.

[21]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[22]  D. Wallwiener,et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.

[23]  C. Blomqvist,et al.  Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients. , 1998, British Journal of Cancer.

[24]  T. Powles,et al.  Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. , 1998, Journal of the National Cancer Institute.

[25]  C. Blomqvist,et al.  Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  P. Delmas,et al.  Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Blomqvist,et al.  Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. , 1997, British Journal of Cancer.

[28]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[29]  A. Sasaki,et al.  Osteolysis and tumor growth are enhanced in sites of increased bone turnover in vivo. (口答発表) , 1994 .

[30]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[31]  P. Ward,et al.  Chemotactic responses of tumor cells to products of resorbing bone. , 1979, Science.

[32]  J. Bingham.  Letter: Lower oesophageal sphincter. , 1974, Lancet.